Shandong Sinobioway Biomedicine Co Ltd (002581) — Net Asset Quality Index
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Net Asset Quality Index of 90.0% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.21 Billion minus total liabilities of CN¥221.51 Million yields net assets of CN¥1.99 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read 002581 total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shandong Sinobioway Biomedicine Co Ltd Net Asset Quality Index Over Time (2007–2024)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 90.0%, representing net assets of CN¥1.99 Billion against total assets of CN¥2.21 Billion CNY. For live market cap and overall valuation, see Shandong Sinobioway Biomedicine Co Ltd market cap and net worth.
Annual Net Asset Quality Index for Shandong Sinobioway Biomedicine Co Ltd (2007–2024)
The table below presents the year-by-year Net Asset Quality Index for Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check how strategically is Shandong Sinobioway Biomedicine Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 92.1% | CN¥2.02 Billion | CN¥2.20 Billion | CN¥173.61 Million | ▼ -0.9 pp |
| 2023 | 93.0% | CN¥2.17 Billion | CN¥2.34 Billion | CN¥163.41 Million | ▲ +6.6 pp |
| 2022 | 86.4% | CN¥2.47 Billion | CN¥2.86 Billion | CN¥389.46 Million | ▼ -3.2 pp |
| 2021 | 89.6% | CN¥2.47 Billion | CN¥2.76 Billion | CN¥286.76 Million | ▼ 0.0 pp |
| 2020 | 89.6% | CN¥2.19 Billion | CN¥2.44 Billion | CN¥254.33 Million | ▲ +19.6 pp |
| 2019 | 70.0% | CN¥2.39 Billion | CN¥3.41 Billion | CN¥1.03 Billion | ▲ +4.3 pp |
| 2018 | 65.7% | CN¥2.82 Billion | CN¥4.29 Billion | CN¥1.47 Billion | ▼ -7.3 pp |
| 2017 | 73.0% | CN¥2.92 Billion | CN¥4.00 Billion | CN¥1.08 Billion | ▼ -21.0 pp |
| 2016 | 94.0% | CN¥2.53 Billion | CN¥2.69 Billion | CN¥160.16 Million | ▲ +5.3 pp |
| 2015 | 88.7% | CN¥2.14 Billion | CN¥2.42 Billion | CN¥271.92 Million | ▼ -8.6 pp |
| 2014 | 97.4% | CN¥749.40 Million | CN¥769.49 Million | CN¥20.08 Million | ▲ +2.0 pp |
| 2013 | 95.4% | CN¥738.31 Million | CN¥773.80 Million | CN¥35.49 Million | ▼ -1.2 pp |
| 2012 | 96.6% | CN¥704.41 Million | CN¥729.02 Million | CN¥24.62 Million | ▼ -0.8 pp |
| 2011 | 97.4% | CN¥672.28 Million | CN¥690.19 Million | CN¥17.91 Million | ▲ +12.8 pp |
| 2010 | 84.6% | CN¥177.34 Million | CN¥209.68 Million | CN¥32.34 Million | ▲ +5.9 pp |
| 2009 | 78.6% | CN¥129.71 Million | CN¥164.95 Million | CN¥35.24 Million | ▼ -2.3 pp |
| 2008 | 80.9% | CN¥116.12 Million | CN¥143.53 Million | CN¥27.41 Million | ▼ -7.0 pp |
| 2007 | 87.9% | CN¥83.94 Million | CN¥95.54 Million | CN¥11.60 Million | — |